Inhibitors support immune therapy for leukemia

September 12, 2017, German Cancer Research Center
Bone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: Wikipedia

New immune therapies are considered a promising lead for treating recurring acute myeloid leukemia (AML). Antibodies are able to eliminate even those cancer cells that cannot be removed via regular therapies. Scientists from the German Cancer Consortium (DKTK) and the Munich University Hospital and Tübingen University Hospital have shown that, in conjunction with certain inhibitors, this form of therapy could be successful in even more patients.

In the German Cancer Consortium (DKTK), the German Cancer Research Center (DKFZ) in Heidelberg joins up as a core center in long-term collaborations with partner university institutes and hospitals all over Germany that are specialized in research and treatment with a focus on oncology.

Acute Myeloid Leukemia (AML) is a malignant blood cancer variety, which derives from the immature precursors of , platelets, and some . AML is the most common acute leukemia in adults. For about a third of patients the cause of the uncontrolled cell division of the malignant cells is a mutation of the growth receptor FLT3. This is why cancer medicine pursues a variety of strategies in attacking this mutated receptor therapeutically, such as with inhibitors or antibodies in cancer .

One such antibody was recently developed in the German Cancer Consortium (DKTK) and is now undergoing clinical trials at the Tübingen University Hospital. The FLT3 antibody marks leukemia cells which remain in the body after a seemingly successful chemotherapy. The marked blood cells are then recognized by the body's own immune cells and will be eliminated.

"Immune therapy solely with the FLT3 antibody, however, is not always successful", explains Philipp Greif, DKTK junior group leader at Munich University Hospital (LMU)." In some cases the FLT3 receptor has mutated so much, that it has largely disappeared from the surface of the leukemia cell and is therefore no longer accessible to the antibody.

In a collaborative study, both the Tübingen and Munich scientists examined the possibility of successfully treating AML via a combination of both substances. They used special inhibitors, so-called kinase inhibitors, in order to bring the mutated FLT3 receptor back to the surface in order to make it susceptible to immune therapy again. This way, more AML were able to be eliminated. "The combination of both treatments worked much better in our pre-clinical trials than just one active substance", said Katrin Reiter, first author of the study.

Both FLT3 inhibitors and FLT3 antibodies are quite advanced in clinical trials. Recently the FLT3 inhibitor midostaurin was approved for use in combination with standard chemotherapy. Follow-up studies will now be conducted to determine which of the available inhibitors are the most suitable to be combined with the FLT3-based immune .

Explore further: New inhibitor drug shows promise in relapsed leukemia

More information: K Reiter et al, Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia, Leukemia (2017). DOI: 10.1038/leu.2017.257

Related Stories

New inhibitor drug shows promise in relapsed leukemia

June 21, 2017
A new drug shows promise in its ability to target one of the most common and sinister mutations of acute myeloid leukemia (AML), according to researchers at the Perelman School of Medicine at the University of Pennsylvania ...

A new target in acute myeloid leukemia

July 16, 2012
Acute myeloid leukemia, a common leukemia in adults, is characterized by aberrant proliferation of cancerous bone marrow cells. Activating mutations in a protein receptor known as FLT3 receptor are among the most prevalent ...

Identification of a novel tyrosine kinase inhibitor for acute myeloid leukemia

March 17, 2016
Acute myeloid leukemia (AML) is a cancer of myeloid stem cells that develops in both adult and pediatric populations. Mutations that cause hyperactivation of the FMS-like tyrosine kinase 3 (FLT3) are commonly found in AML, ...

Longer survival for midostaurin and chemotherapy in AML with FLT3

June 26, 2017
(HealthDay)—For patients with acute myeloid leukemia (AML) and a FLT3 mutation, midostaurin plus chemotherapy is associated with prolonged overall and event-free survival, according to a study published online June 23 in ...

Rydapt approved for adults with acute myeloid leukemia

April 28, 2017
(HealthDay)—Rydapt (midostaurin) has been approved by the U.S. Food and Drug Administration, in combination with chemotherapy, to treat adults with acute myeloid leukemia (AML) who have a specific genetic mutation dubbed ...

Drug against breast cancer is also highly potent against a frequent form of leukaemia

May 17, 2016
Cancer cells have an abnormal cell division and survival machinery - they grow faster than they die. For their permanent development, they produce an excess of growth factors and nutrients and block the body's own safety ...

Recommended for you

Breast cancer researcher warns against online genetic tests

June 18, 2018
We have never been so fascinated by the secrets inside our cells.

Genomics offers new treatment options for infants with range of soft tissue tumors

June 18, 2018
The genetic causes of a group of related infant cancers have been discovered by scientists at the Wellcome Sanger Institute, the University of Wuerzburg and their collaborators. Whole genome sequencing of tumours revealed ...

Non-coding DNA reveals a route by which advanced prostate cancer resists treatment

June 15, 2018
Two research teams converge on epigenetic switches that feed treatment-resistant metastatic prostate tumors. This research highlights the value of exploring gene regulation and large-scale structural changes in the cancer ...

Researchers peer inside cells to spy on cancer's on-off switch

June 15, 2018
Forty years after researchers first discovered it in fruit flies, a once-obscure cluster of proteins called PRC2 has become a key target for new cancer-fighting drugs, due to its tendency—when mutated—to bind to and silence ...

PIM-2 protein kinase regulates T-cell activity differently than PIM-1 or PIM-3 isoform

June 15, 2018
The PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity, while PIM-1 and PIM-3 are positive regulators, report Medical University of South Carolina (MUSC) investigators in an article ...

Gene testing could identify men with prostate cancer who may benefit from immunotherapy

June 14, 2018
Scientists have identified a pattern of genetic changes that could pick out men with advanced prostate cancer who are likely to benefit from immunotherapy.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.